Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

17 Apr 2019 07:00

RNS Number : 3877W
Cambridge Cognition Holdings PLC
17 April 2019
 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Grant of Options

 

The neuroscience technology company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technologies to assess brain health, announces that on 16 April 2019, the Company granted options ("Options") over a total of 189,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and the Company's unapproved option scheme.

Of these Options:

- 63,000 were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company; and

- 126,000 were granted to other employees of the Company.

60,000 of the Options granted to PDMRs together with 105,000 of the 126,000 Options granted to other employees are exercisable at a price of 72 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

- 55% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for the final 10 trading days of 2020 is greater than 150 pence per Ordinary Share. A pro rata sliding scale will apply if the average closing mid-market price of an Ordinary Share for the final 10 trading days of 2020 is between 110 pence and 150 pence per Ordinary Share; and

- 45% of the Options granted will vest if the profit after tax as reported in the audited statutory accounts of the Group for the two financial years ended 31 December 2019 and 31 December 2020 when added together is greater than £nil. Should this requirement not be met, 20% of the total shares granted will vest if the profit after tax as reported in the audited statutory accounts of the Group for the financial year ended 2020 is greater than £nil.

The remaining 24,000 Options (including 3,000 awarded to PDMRs) are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 973,406, representing approximately 4.03% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Jennifer Barnett - Chief Scientific Officer

Ricky Dolphin - Chief Technology Officer

Malcolm Gates - Director of Group Finance

Mark Miller-Holliday - Director of International Sales and Business Development

2.

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 16 April 2019

 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares

 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Jennifer Barnett - 25,000 Options

Ricky Dolphin - 10,000 Options

Malcolm Gates - 26,500 Options

Mark Miller-Holliday - 1,500 Options

d)

Aggregated information:

· Aggregated volume

· Price

n/a

e)

Date of the transaction

16 April 2019

f)

Place of the transaction

Outside a trading venue

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Enquiries

Cambridge Cognition Holdings PLC

 

Steven Powell, Chief Executive Officer

Nick Walters, Chief Financial Officer

Tel: 01223 810 700

 

 

 

finnCap Ltd (NOMAD and Joint Broker)

Tel: 020 7220 0500

Geoff Nash / Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(ECM)

 

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

 

 

IFC Advisory Limited (Financial PR and IR)

Tel: 020 3934 6630

Graham Herring/ Miles Nolan/ Zach Cohen

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHXQLFFKZFZBBB
Date   Source Headline
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.